Pfizer (NYSE:PFE) Upgraded to Buy at Wall Street Zen

Wall Street Zen upgraded shares of Pfizer (NYSE:PFE) from a hold rating to a buy rating in a research note released on Sunday morning,Wall Street Zen reports.

PFE has been the subject of several other reports. HSBC increased their price objective on Pfizer from $28.00 to $30.00 and gave the company a “hold” rating in a research note on Thursday. Guggenheim lowered their target price on shares of Pfizer from $35.00 to $31.00 and set a “buy” rating on the stock in a research note on Friday, August 7th. JPMorgan Chase & Co. dropped their target price on shares of Pfizer from $30.00 to $28.00 and set a “neutral” rating for the company in a report on Wednesday, July 8th. Bank of America reduced their target price on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a research report on Friday, July 10th. Finally, Royal Bank Of Canada raised shares of Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 price target on the stock in a research note on Tuesday, June 9th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $28.39.

Pfizer Trading Down 0.1%

PFE stock opened at $27.69 on Friday. Pfizer has a 12-month low of $23.58 and a 12-month high of $29.21. The business’s 50-day moving average is $26.35 and its 200 day moving average is $26.36. The company has a current ratio of 1.27, a quick ratio of 0.96 and a debt-to-equity ratio of 0.71. The stock has a market cap of $157.82 billion, a price-to-earnings ratio of 36.43, a PEG ratio of 1.86 and a beta of 0.34.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, beating analysts’ consensus estimates of $0.68 by $0.09. The business had revenue of $15.03 billion during the quarter, compared to analysts’ expectations of $14.40 billion. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.The business’s revenue was up 2.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.78 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, sell-side analysts anticipate that Pfizer will post 2.98 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th were paid a dividend of $0.43 per share. The ex-dividend date of this dividend was Friday, July 24th. This represents a $1.72 dividend on an annualized basis and a yield of 6.2%. Pfizer’s payout ratio is 226.32%.

Institutional Trading of Pfizer

Hedge funds and other institutional investors have recently modified their holdings of the stock. California State Teachers Retirement System increased its position in Pfizer by 2,320.6% during the second quarter. California State Teachers Retirement System now owns 217,981,455 shares of the biopharmaceutical company’s stock worth $5,248,993,000 after purchasing an additional 208,976,273 shares during the last quarter. Norges Bank acquired a new position in Pfizer in the 4th quarter valued at about $1,830,986,000. Bank of America Corp DE purchased a new stake in shares of Pfizer in the 2nd quarter valued at approximately $1,049,602,000. BlackRock Inc. grew its stake in shares of Pfizer by 6.3% in the 2nd quarter. BlackRock Inc. now owns 529,670,433 shares of the biopharmaceutical company’s stock valued at $12,754,464,000 after buying an additional 31,412,883 shares during the period. Finally, Morgan Stanley increased its holdings in shares of Pfizer by 19.2% during the 4th quarter. Morgan Stanley now owns 89,113,604 shares of the biopharmaceutical company’s stock worth $2,218,929,000 after buying an additional 14,342,946 shares during the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Company Profile

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its portfolio addresses a range of therapeutic areas, including oncology, inflammation and immunology, internal medicine, hospital care, rare diseases and infectious diseases. The company serves patients and healthcare providers in markets worldwide.

Pfizer’s products include the Comirnaty COVID-19 vaccine, the Prevnar family of pneumococcal vaccines, and medicines such as Eliquis, Ibrance, Vyndaqel and Zavzaret.